Raltegravir-based regimens are effective in HIV-1 group O-infected patients.

Agnès Depatureaux; Marie Leoz; Gwenae Le Moal; Jean-Paul Pathé; Juliette Pavie; Dominique Batisse; Vincent Daneluzzi; Philippe Genet; Laurence Gerard; Anne-Sophie Lascaux-Cametz

doi:10.1097/QAI.0b013e31826327c4

Raltegravir-based regimens are effective in HIV-1 group O-infected patients.

Identifier:nobleid.org/w1/20260515/899C3CC4

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/899C3CC4.svg?ark=w1%2F20260515%2F899C3CC4)](https://nobleid.org/work/w1/20260515/899C3CC4)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Anne-Sophie Lascaux-Cametz

Claim authorship of this work

Raltegravir-based regimens are effective in HIV-1 group O-infected patients.

Identifier:nobleid.org/w1/20260515/899C3CC4

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/899C3CC4.svg?ark=w1%2F20260515%2F899C3CC4)](https://nobleid.org/work/w1/20260515/899C3CC4)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Anne-Sophie Lascaux-Cametz

Claim authorship of this work